既往BPH手术干预对前列腺癌冷冻消融术肿瘤学及功能学结局的影响
本研究基于3831例接受原发性全腺体前列腺冷冻消融术的前列腺癌患者,比较有既往BPH介入治疗史(160例)与无此病史者的肿瘤学和功能学结局。结果显示,既往BPH介入治疗不增加生化进展风险或直肠尿道瘘风险,但显著增加术后尿潴留和新发尿失禁的风险。
要点
- 既往BPH介入治疗不增加冷冻消融术后生化进展风险(5年PFS无差异,p=0.3)。
- 既往BPH介入治疗显著增加术后尿潴留(OR 1.9,p=0.015)和尿失禁(OR 2.13,p<0.001)风险。
- 既往BPH介入治疗未增加直肠尿道瘘或新发勃起功能障碍风险。
核心结论
- 既往BPH介入治疗不影响前列腺癌冷冻消融术后的肿瘤学结局。
- 既往BPH介入治疗增加术后尿潴留和新发尿失禁风险,但不增加直肠尿道瘘或ED风险。
研究设计与样本
- 回顾性队列研究,纳入3831例接受原发性全腺体前列腺冷冻消融术的前列腺癌患者。
- 其中160例有既往BPH介入治疗史(经尿道针消融6例、经尿道微波热疗9例、经尿道前列腺电切术145例)。
- 排除有药物治疗或未明确BPH治疗史的患者。
主要发现
- 未调整分析中,既往BPH介入治疗组术后尿潴留发生率为17.5%,无治疗组为9.6%(p=0.001)。
- 新发尿失禁发生率分别为39.9%和19.4%(p>0.001,原文如此)。
- 直肠尿道瘘风险无显著差异(p=0.84),术后12个月新发ED风险无显著差异(p=0.08)。
- 多因素回归显示,既往BPH介入治疗与尿潴留风险增加相关(OR 1.9,p=0.015),与新发尿失禁风险增加相关(OR 2.13,p<0.001)。
- 5年Kaplan-Meier生存分析显示生化无进展生存率无统计学显著差异(p=0.3);冷冻消融后因故活检阳性率两组分别为25.4%和28.7%(p=0.59)。
临床怎么用
- 对计划接受前列腺冷冻消融术的前列腺癌患者,应询问既往BPH介入治疗史。
- 有BPH介入治疗史者术后应加强尿潴留和尿失禁的监测与预防。
- 既往BPH介入治疗史不影响肿瘤学结局,不应作为冷冻消融术的禁忌。
局限性
- 回顾性研究设计,可能存在选择偏倚。
- 既往BPH介入治疗组样本量较小(160例),且不同干预方式构成不均。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess whether prior interventional treatment for benign prostatic hyperplasia (BPH) influences oncologic or functional outcomes following primary whole-gland prostate cryoablation. METHODS: Among 3831 men with prostate cancer who underwent primary whole-gland prostate cryoablation, we identified 160 with a history of prior BPH interventional therapy including transurethral needle ablation (n = 6), transurethral microwave thermotherapy (n = 9), or transurethral resection of the prostate (n = 145). Patients with a history of medically treated or unspecified BPH therapy were excluded from the study. Oncological and functional outcomes were compared between men with and without prior BPH interventional therapy. RESULTS: In unadjusted analyses, prior interventional BPH therapy was associated with higher risks of postoperative urinary retention (17.5% vs. 9.6%, p = 0.001) and new-onset urinary incontinence (39.9% vs. 19.4%, p > 0.001) compared with no prior therapy. Interventional BPH therapy was not correlated with the risk of developing a rectourethral fistula (p = 0.84) or new-onset erectile dysfunction (ED) at 12 months (p = 0.08) following surgery. On multivariable regression, prior interventional BPH therapy was associated with increased risk of urinary retention (OR 1.9, 95%, p = 0.015) and new-onset urinary incontinence (OR 2.13, p < 0.001). The estimated 5 years Kaplan-Meier survival analysis showed no statistically significant difference (p = 0.3) in biochemical progression free survival between those who underwent interventional BPH therapy compared with those who did not. Local disease recurrence assessed by post cryoablation positive for-cause prostate biopsy showed no significant difference between the two groups (25.4% vs. 28.7%, p = 0.59). CONCLUSIONS: Prior interventional BPH therapy did not affect the oncologic outcomes nor did it increase the risk of rectourethral fistula or ED in sexually performing patients prior to cryosurgery. Prior interventional BPH therapy was associated with increased risk of urinary retention and incontinence after primary whole-gland prostate cryoablation for prostate cancer.
引用
- ElShafei A, DeWitt-Foy M, Calaway A, et al. Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer? Prostate Cancer Prostatic Dis. 2021. PMID: 33483626. doi:10.1038/s41391-020-00306-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。